- Home
- USCB vs ACRS Comparison
USCB vs ACRS Comparison
Compare USCB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USCB | ACRS |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.8M | 314.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | USCB | ACRS |
|---|---|---|
| Price | $18.87 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.00 | $9.75 |
| AVG Volume (30 Days) | 46.5K | ★ 1.3M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 50.85 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $92,331,000.00 | $15,742,000.00 |
| Revenue This Year | $26.31 | N/A |
| Revenue Next Year | $15.23 | N/A |
| P/E Ratio | $11.93 | ★ N/A |
| Revenue Growth | ★ 28.61 | N/A |
| 52 Week Low | $15.39 | $1.05 |
| 52 Week High | $20.49 | $3.48 |
Technical Indicators
Market Signals| Indicator | USCB | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 54.12 |
| Support Level | $18.88 | $2.78 |
| Resistance Level | $19.95 | $3.09 |
| Average True Range (ATR) | 0.64 | 0.19 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 39.40 | 35.25 |
Price Performance
Historical ComparisonAbout USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.